Disease continuum centered on Parkinson's disease

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology Pub Date : 2025-01-29 DOI:10.1016/j.euroneuro.2025.01.002

Ming Zheng

{"title":"Disease continuum centered on Parkinson's disease","authors":"Ming Zheng","doi":"10.1016/j.euroneuro.2025.01.002","DOIUrl":null,"url":null,"abstract":"<div><div>Parkinson’s disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals—including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems. Moreover, comorbidities were classified based on their temporal relationship to PD diagnosis: pre-PD comorbidities, such as hypertension and autoimmune disorders, may act as risk factors of PD onset, while post-PD comorbidities, including Alzheimer’s disease and renal disorders, highlight the systemic consequences of PD progression. These findings emphasize the critical need for early detection and intervention to manage comorbidities and potentially delay PD onset. Furthermore, this study advocates for integrated diagnostic and therapeutic strategies targeting shared risk factors, advancing a precision-medicine approach to improve patient care and long-term management of PD.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"93 ","pages":"Pages 19-21"},"PeriodicalIF":6.1000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25000021","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Parkinson’s disease (PD), once viewed as a neurodegenerative disorder, is now increasingly recognized as part of a broader disease continuum, intricately linked to comorbidities across various organ systems. This study provides a snapshot of the disease continuum centered on PD, using a disease-wide association study (DWAS) involving 392,423 individuals—including 4,235 PD cases. This DWAS identifies disease clusters of PD comorbidities across the musculoskeletal, circulatory, digestive, and respiratory systems. Moreover, comorbidities were classified based on their temporal relationship to PD diagnosis: pre-PD comorbidities, such as hypertension and autoimmune disorders, may act as risk factors of PD onset, while post-PD comorbidities, including Alzheimer’s disease and renal disorders, highlight the systemic consequences of PD progression. These findings emphasize the critical need for early detection and intervention to manage comorbidities and potentially delay PD onset. Furthermore, this study advocates for integrated diagnostic and therapeutic strategies targeting shared risk factors, advancing a precision-medicine approach to improve patient care and long-term management of PD.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

European Neuropsychopharmacology 医学-精神病学

CiteScore

10.30

自引率

5.40%

发文量

730

审稿时长

41 days

期刊介绍： European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.